BioVie (NASDAQ:BIVI) Announces Quarterly Earnings Results

BioVie (NASDAQ:BIVIGet Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, Zacks reports.

BioVie Stock Performance

Shares of NASDAQ BIVI traded down $0.06 during trading hours on Tuesday, reaching $1.80. 400,384 shares of the stock were exchanged, compared to its average volume of 949,359. The firm has a market capitalization of $31.99 million, a price-to-earnings ratio of -0.16 and a beta of 0.47. The stock’s fifty day simple moving average is $2.20 and its 200 day simple moving average is $2.29. BioVie has a 52 week low of $1.04 and a 52 week high of $33.10.

About BioVie

(Get Free Report)

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.

Recommended Stories

Earnings History for BioVie (NASDAQ:BIVI)

Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.